Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis
NCT02274792
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
132
Enrollment
INDUSTRY
Sponsor class
Conditions
Plaque Psoriasis
Interventions
DRUG:
Etanercept
Sponsor
Amgen